• Maze Therapeutics CEO Jason V. Coloma sold 34,501 common shares on Aug. 3, 2026 at about $26.71–$27.09 each.
• Sales were reported as indirect holdings through the Coloma 2021 Irrevocable Trust and the Coloma Family Trust.
• Post-transaction beneficial ownership: 20,744 shares in the Coloma 2021 Irrevocable Trust; 255,263 shares in the Coloma Family Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001676170-26-000016), on August 05, 2026, and is solely responsible for the information contained therein.